[Radioiodine therapy of functional autonomy of the thyroid gland. Treatment results in view of pretreatment scintigraphic diagnosis and early response of triiodothyronine levels to treatment].
OBJECTIVE
The goal of this retrospective study was to evaluate the results of radioiodine therapy of thyroid autonomy with respect to the underlying scintigraphic pattern, administered I-131 doses and pretherapeutic Tc-99m and I-131 uptake. Furthermore, early post-therapeutic free triiodothyronine (FT3) levels were measured during the first 6 weeks after radioiodine therapy with respect to a FT3-increase.


METHODS
Thyroid autonomy in 632 patients was followed for at least 3 months (mean 10.9 months). The patients were divided into several groups based on scintigraphic pattern of unifocal (UA), a multifocal (MFA), a focal/disseminated (FDA) and a disseminated (DA) autonomy. The early effects of therapy on thyroid function were assessed by evaluation of FT3 values of 786 patients during the 1st, 2nd, 3rd, 4th and 6th week after therapy.


RESULTS
Successful elimination of thyroid autonomy as defined by normalization of FT3 and TSH levels was observed in 92.1% (582/632) of the patients. In 2.2% (14/632) of the patients, immunogenic hyperthyroidism following I-131 therapy was observed. There was no significant difference in the success rates in patients with UA and MFA of 94.9% and 96.1%, respectively, using similar target doses based on the amount of autonomous tissue. The success rate in MFA (96.6%) was similar if target dose was calculated based on the volume of the whole thyroid gland. Compared to MFA (96.6%), however, FDA and DA were associated with significantly lower success rate with 82.7% and 75.5%, respectively, although the target doses were not significantly different. Considering the quantitative Tc-99m uptake prior to therapy, there was no significant difference in the success rate for Tc-99m uptake < or = 3% and > 3%, while the success rate in patients with I-131 uptake of < or = 50% was significantly higher (p = 0.032) than in those with an uptake of > 50%. The determination of FT3 levels during the first 6 weeks after radioiodine therapy revealed a dependence of the FT3 decrease and FT3 increase on the scintigraphic pattern and thyroid function. Patients with FDA and DA with hyperthyroidism showed an increase of FT3 (> 2 to 14.7 pmol/l) in 11 to 18% of the cases, during the first 2 weeks after therapy which occurred significantly more frequently in patients with FDA and DA than in UA and MFA. A similar increase in FT3 level in patients with FDA and DA compared to patients with UA and MFA was observed in 317 patients with euthyroid pretherapeutic hormone levels. A decrease in FT3 level following radioiodine therapy was observed significantly more often and earlier in patients with UA and MFA with hyperthyroid values than in patients with FDA and DA during the first 6 posttherapeutic weeks. Concerning patients with euthyroid FT3 levels, the decrease in FT3 level was observed significantly more frequently in patients with UA and MFA only after 6 weeks following radioiodine therapy.


CONCLUSIONS
In contrast to the multifocal autonomy (MFA), the target dose of 150 to 200 Gy based on total thyroid volume did not result in a comparably high success rate of approximately 95% in disseminated and focal/disseminated types of thyroid autonomy. Therefore, an increase of target dose of 200 to 300 Gy is recommended. The transient FT3 increase particularly observed in FDA and DA in the first weeks following radioiodine therapy makes short-term controls of thyroid function necessary, especially in patients with cardiac risk, in order to initiate necessary therapy.
Langhammer
H R
HR
Nuklearmedizinische Klinik und Poliklinik, Technischen Universität München.
Laubenbacher
C
C
Hirsch
C
C
Klingele
C
C
Spyra
J L
JL
Senekowitsch-Schmidtke
R
R
Schwaiger
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D013959:Thyroid Diseases / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000528:radiation effects; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000097:blood*
D007457:Iodine Radioisotopes; D014284:Triiodothyronine